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Abstract
The long-term control of tuberculosis (TB) will require the development of more effective anti-TB vaccines, as the only
licensed vaccine, Mycobacterium bovis bacille Calmette-Gue ´rin (BCG), has limited protective efficacy against infectious
pulmonary TB. Subunit vaccines have an improved safety profile over live, attenuated vaccines, such as BCG, and may be
used in immuno-compromised individuals. MPT83 (Rv2873) is a secreted mycobacterial lipoprotein expressed on the surface
of Mycobacterium tuberculosis. In this study, we examined whether recombinant MPT83 is recognized during human and
murine M. tuberculosis infection. We assessed the immunogenicity and protective efficacy of MPT83 as a protein vaccine,
with monophosphyl lipid A (MPLA) in dimethyl-dioctadecyl ammonium bromide (DDA) as adjuvant, or as a DNA vaccine in
C57BL/6 mice and mapped the T cell epitopes with peptide scanning. We demonstrated that rMPT83 was recognised by
strong proliferative and Interferon (IFN)-c-secreting T cell responses in peripheral blood mononuclear cells (PBMC) from
patients with active TB, but not from healthy, tuberculin skin test-negative control subjects. MPT83 also stimulated strong
IFN-c T cell responses during experimental murine M. tuberculosis infection. Immunization with either rMPT83 in MPLA/DDA
or DNA-MPT83 stimulated antigen-specific T cell responses, and we identified MPT83127–135 (PTNAAFDKL) as the dominant
H-2
b-restricted CD8
+ T cell epitope within MPT83. Further, immunization of C57BL/6 mice with rMPT83/MPLA/DDA or DNA-
MPT83 stimulated significant levels of protection in the lungs and spleens against aerosol challenge with M. tuberculosis.
Interestingly, immunization with rMPT83 in MPLA/DDA primed for stronger IFN-c T cell responses to the whole protein
following challenge, while DNA-MPT83 primed for stronger CD8
+ T cell responses to MPT83127–135. Therefore MPT83 is a
protective T cell antigen commonly recognized during human M. tuberculosis infection and should be considered for
inclusion in future TB subunit vaccines.
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Introduction
One-third of the world’s population is infected with Mycobac-
terium tuberculosis, the pathogen responsible for tuberculosis (TB). In
2010, the prevalence of active TB cases was estimated to be 178/
100,000, resulting in nearly nine millions new cases and 1.5
million deaths worldwide [1]. The incidence has declined steadily
at only at a rate 1.3% per year since 2002, despite the
implementation of the Directly Observed Therapy – Shortcourse
(DOTS) strategy using observed anti-microbial therapy and the
extended program of immunization with the only currently-
licensed TB vaccine, Mycobacterium bovis, bacille Calmette-Gue ´rin
(BCG) in high burden countries. Although BCG is effective against
severe forms of childhood TB, its protective efficacy against
pulmonary TB in adolescents and adults has ranged from 0 to
80% [2]. Several approaches have been taken to either improve
the protection afforded by BCG or replace it with a more effective
vaccine. Modified BCG vaccines which have entered clinical trials
include recombinant BCG expressing listeriolysin (rBCGDure::hly)
[3] and BCG over-expressing Antigen 85B (rBCG30) [4]. Subunit
vaccines have the advantage of safety when used in immune-
compromised individuals, such as those infected with the human
immunodeficiency virus (HIV), and can be used alone or to boost
immunity in individuals previously immunized with BCG [5].
Recently a number of subunit vaccines for TB have entered
clinical trials, these include fusion proteins based on Antigen (Ag)
85B and ESAT-6 (HyVac1) [6], Ag85B and TB10.4 (HyVac4) [7]
and Rv1196 and Rv0125 (Mtb72f) [8]; as well as the non-
replication Modified Vaccinia Ankara expressing Ag85A
(MVA85A) [9].
These first generation subunit vaccines contain only a small
number of the possible M. tuberculosis antigens recognised by
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expand the repertoire of candidate antigens. Criteria for the
inclusion of M. tuberculosis proteins in subunit vaccines include their
recognition by T cells of M. tuberculosis-infected humans, their
ability to induce protective immunity in experimental infection,
and their suitability for mass production and formulation with
adjuvants [10].
MPT83 (Rv2873) is a cell wall-associated lipo-glycoprotein of
M. tuberculosis, whose function is unknown, although it has been
suggested to play a role in adhesion and dissemination based on
sequence analysis [11]. Its homologues in M. bovis, MPB83 and
MBP70, are sero-dominant antigens during M. bovis infection in
both cattle and badgers [12,13]. DNA vaccination studies in cattle
revealed that MPB83 is immunogenic, generating strong T cell
and B cell responses [14–16]. Interestingly, pre-treatment of
animals with anti-MPB83 antibodies resulted in increased survival
during M. bovis infection [17]. The expression of MBP83 varies
between different strains of BCG owing to a point mutation in the
positive regulator, Sigma factor K (SigK) [18]. During in vitro
culture M. tuberculosis expresses relatively small quantities of
MPT83 and MPT70, but the expression level of MPT83 is
increased during infection [11].
In this study we have investigated the immuno-reactivity of
MPT83 in human and experimental tuberculosis, and its capacity
to induce protective immunity. The recombinant MPT83
expressed in Escherichia coli was recognized by the majority of
human TB patients, as well as during murine M. tuberculosis
infection. DNA vaccine expressing MPT83 elicited antigen-
specific IFN-c secreting T cell responses, and using overlapping
peptides spanning the entire sequence of MPT83, the H-2
b-
restricted CD4
+ and CD8
+ T cell epitopes were identified. Both
DNA and protein vaccine formulations generated protective
immunity against murine M. tuberculosis infection. Therefore
MPT83 is an important antigen with defined T cell responses in
humans and mice, and should be considered for inclusion in future
subunit vaccine candidates.
Results
Expression and Characterisation of Recombinant MPT83
The full length MPT83 was expressed as a recombinant protein
in E. coli BL21 (DE3), solubilized and purified using the Talon
Co
2+ based metal affinity resin. The purified rMPT83 protein with
an N-terminal HIS-tag was refolded, and a single protein with a
relative molecular mass (Mr) of 28 kDa was identified following
separation by SDS-PAGE (Fig. 1A). This compares to the
predicted molecular mass of 26 kDa for MPT83.
To determine the location of MPT83 in M. tuberculosis, high-titre
antibodies against MPT83 were raised in mice immunized
subcutaneously with rMPT83 and used to probe sub-cellular
preparations of M. tuberculosis by immunoblotting (Fig. 1B).
MPT83 in M. tuberculosis fractions was detected as a band at
25 kDa, while the rMPT83 was detected at 28 kDa. MPT83 was
abundant in the whole cell lysate (Fig. 1B, lane 8), and weak bands
were detected in Tx-114 membrane protein (lane 4) and cell wall
protein fractions (Fig. 1B, lane 5 and 6). By contrast, no MPT83
was detected in the fractions containing cytoplasmic proteins
(Fig. 1B, lane 3) and culture filtrate proteins (Fig. 1B, lane 7).
MPT83 is Recognized as a T Cell Antigen During
M. tuberculosis Infection
To determine if MPT83 is recognized during M. tuberculosis
infection, splenocytes from M. tuberculosis infected mice were
stimulated either with rMPT83, or M. tuberculosis CFP as positive
control. The number of antigen-specific IFN-c secreting T cells
was enumerated by ELIspot assay. rMPT83 protein stimulated a
mean antigen-specific IFN-c response of 7466169 SPC/10
6 cells,
compared to 9116148 SPC/10
6 cells for CFP-stimulated spleno-
cytes and 4567.2 SFC/10
6 cells in unstimulated splenocytes
(Fig. 1C).
Human T Cell Responses to MPT83
M. bovis MBP83, which has identical amino acid sequence to
MPT83, is highly immunogenic in both cattle and other
ruminants. To study whether MPT83 is recognised during human
M. tuberculosis infection, PBMCs from 28 patients with active TB
(13 males, 15 females, ages 22–74) and 20 TST-negative subjects
(10 males, 10 females, ages 22–53) were stimulated with rMPT83,
and both T cell proliferative and IFN-c responses were measured.
PBMCs from subjects with active TB proliferated significantly
more to MPT83 (mean
3H-thymidine incorporation 5,869 CPM)
than those from TST-negative subjects (641 CPM) (p,0.0001),
with 20/28 TB patients having an MPT83-specific proliferative
response of DCPM.3,000 compared to 1/20 TST-negative
subjects (Fig. 2A). Similar increases in proliferation were observed
when the PBMCs were stimulated with M. tuberculosis CFP, with
25/25 TB patients having CFP-specific proliferative response of
DCPM .3,000 compared to 6/20 TST-negative subjects. Anal-
ysis of the culture supernatant revealed significantly higher levels
of secreted IFN-c from the PBMCs of active TB subjects (mean
325 pg/ml) than those of TST-negative subjects (mean 20 pg/ml)
following stimulation with rMPT83 (p,0.0001) (Fig. 2B). In all,
21/28 TB patients had an MPT83-specific IFN-c T cell response
of .100 pg/ml compared to 1/20 TST-negative subjects. All TB
patients had a CFP-specific IFN-c response of .100 pg/ml
compared to 6/20 TST-negative subjects.
Immunogenicity of DNA-MPT83
To investigate the immunogenicity of MPT83, mice were
immunized with the DNA vaccine encoding the entire MPT83
protein. Antigen-specific IFN-c secreting T cells, measured by
ELIspot, were significantly more frequent in splenocytes from
DNA-MPT83-immunized mice than those from mice immunized
with the control vaccine, pcDNA3 (Fig. 3A). Splenocytes were also
stimulated with rMPT83 for 72 h, and significantly increased
levels of IFN-c were secreted by splenocytes from DNA-MPT83
immunized mice compared to those from mice immunized with
the control DNA vaccine, 2405.906584.3 pg/ml and
124.45643.79 pg/ml, respectively (Fig. 3B).
Murine T Cell EPITOPES within MPT83
Having shown that rMPT83 is recognized by T cells from both
M. tuberculosis-infected and DNA-MPT83-immunized mice, we
next examined the pattern of responses to 22 overlapping 15-mer
peptides spanning the length of MPT83 protein in order to map
the immunodominant T cell epitopes within MPT83. In C57BL/
6 mice immunized with DNA-MPT83, the frequencies of IFN-c
producing cells were the highest in splenocytes stimulated with
peptides 13 (MPT83121–135) and 14 (MPT83131–145) (Fig. 4A).
Weaker responses were also observed when cells were stimulated
with peptide 9 (MPT8381–95), peptide 5 (MPT8341–55) and peptide
1 (MPT831–15). When binding of class II MHC molecules to the T
cell receptors on CD4
+ T cells were inhibited using anti-L3T4a
mAb (GK1.5), responses to peptides 13 and 14 remained
unaffected, while the response to peptide 9 was abolished
(Fig. 4B). Weak responses to peptides 1 and 5 were also not
affected by CD4
+ T cell inhibition. This suggests that peptide 9
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b-restricted CD4
+ T cell epitope and peptides 13
and 14 an H-2
b-restricted CD8
+ T cell.
To confirm the identity of H-2
b-restricted T cell epitopes, CD4
+
and CD8
+ T cells from the spleens of DNA-MPT83-immunized
mice were purified by flow cytometric sorting and stimulated with
irradiated syngeneic splenocytes and peptides 1, 5, 9, 13, and 14,
and the IFN-c T cell responses measured by ELIspot. Modest
IFN-c T cell responses to peptides 5 and 9 were observed with the
purified CD4
+, but not CD8
+, T cells (Figs. 5A and B). By
contrast, a high frequency of IFN-c producing T cells was
observed following stimulation of purified CD8
+ T cells with
peptide 13 alone, and not with the CD4
+ T cells. Therefore,
peptide 13 contains a dominant H-2
b-restricted CD8
+ T cell
epitope, while peptides 5 and 9 may contain CD4
+ T cell epitopes.
Figure 1. The expression and detection of the recombinant MPT83 protein. Full length mpt83 was cloned into pET19b and expressed in
E. coli BL21. (A) Following Co
2+ affinity chromatography the 28 kDa purified protein was visualized by SDS-PAGE. Lane 1, Molecular weight marker;
lane 2, purified rMPT83 500 ng. (B) Coomassie stained SDS-PAGE and anti-MPT83 immunoblot of purified rMPT83 and M. tuberculosis sub-cellular
fractions. Lane 1, Molecular weight marker; lane 2, purified rMPT83 protein; lane 3, cytoplasmic proteins; lane 4, Tx114 fraction; lane 5, cell wall
fraction; lane 6, soluble cell wall fraction; lane 7, culture filtrate proteins; lane 8, whole cell lysate. (C) The number of antigen-specific IFN-c- secreting T
cells (mean6SEM) in splenocytes from M. tuberculosis-infected C57BL/6 mice (n=3) following stimulation with rMPT83, M. tuberculosis culture filtrate
protein (CFP) and media alone for 16 h. The data are representative of two independent experiments and the statistical significance was determined
by the Student’s t-test (**, p,0.01).
doi:10.1371/journal.pone.0034991.g001
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b-restricted CD8
+ T Cell Epitope in MPT83
To resolve further the H-2
b-restricted CD8
+ T cell epitope, we
examined the binding scores of nonameric and octameric peptides
within peptide 13 to both H-2K
b and H-2D
d haplotypes of class I
MHC molecules using the online prediction algorithm SYF-
PEITHI. The octameric peptide 13-8.2 (TNAAFDKL) had the
highest predicted binding for H-2D
b with a score of 22. The
nonameric peptides 13-7 (PTNAAFDKL) and 13-5 (FAPT-
NAAFD) were second and third with binding scores of 12 and 8
respectively. No peptides within peptide 13 were predicted to bind
H-2K
b. Splenocytes from DNA-MPT83 immunized mice were
then stimulated with the set of octameric and nonameric peptides
within peptide 13, which are summarized in Table 1. Splenocytes
from both pcDNA3 and DNA-MPT83 immunized mice respond-
ed to stimulation with the mitogen Con A. Only two out of the
nine peptides induced IFN-c T cell responses. Peptide 13-7
stimulation induced the greatest frequency of IFN-c producing
cells, followed by peptide 13-8.2. In both instances the frequencies
of IFN-c producing cells were not as high as those induced by
stimulation with the 15-mer peptide 13 (Fig. 6).
Protective Efficacy of MPT83 DNA and Protein Vaccines
The protective efficacy of MPT83 as DNA and protein vaccine
was assessed. Following three immunizations with DNA-MPT83
or control DNA vaccine and six weeks rest, C57BL/6 mice were
infected with M. tuberculosis by aerosol, and the bacterial loads in
the lung and spleen were enumerated four weeks after infection.
Immunization with DNA-MPT83 conferred significant protection
in both the lungs (p,0.001) and the spleen (p,0.001) compared to
control DNA vaccine (Figs. 7A and B). C57BL/6 mice were also
immunized with rMPT83 in MPLA/DDA adjuvant or adjuvant
alone three times, rested six weeks and challenged with
M. tuberculosis. The recombinant protein in MPLA/DDA also
stimulated significant protection compared to adjuvant alone, with
at least 1.0 log10 protection in both the lung (p,0.0001) and the
spleen (p,0.05) (Figs. 7C and D). BCG immunization also induced
protection in both the lung and spleen (Fig. 7). Antigen-specific T
cell responses in the draining MLN were also assessed after M.
tuberculosis challenge. Both the immunized and control mice
developed IFN-c responses to M. tuberculosis CFP (Fig. 8A). Mice
immunized with DNA-MPT83, but not control DNA or MPT83/
MPLA/DDA, (Fig. 8B) were primed for a strong T cell response to
the defined CD8
+ T cell epitope, MPT83127–135. By contrast, mice
immunized with MPT83/MPLA/DDA and infected with M.
tuberculosis developed a high frequency of antigen-specific IFN-c T
cells to the whole MPT83 protein, consistent with a CD4
+ T cell
response, and no significant response to the defined CD8
+ T cell
epitope (Fig. 8C).
Discussion
M. tuberculosis proteins to be considered for inclusion in anti-TB
subunit vaccines must be immunogenic in the majority of TB
patients, lack cross-reactivity with human proteins, and stimulate
protective immunity in experimental models of M. tuberculosis
infection. To date, there are six subunit vaccines based on one or
two mycobacterial proteins with these characteristics that have
entered phase I and II clinical trials [19–22]. This study has
identified MPT83 as an additional candidate with similar features
to be considered for inclusion in anti-TB vaccines. MPT83 was
recognised during both murine and human M. tuberculosis infection.
Peripheral blood T cells from the majority of patients with active
TB, but not from tuberculin-negative healthy subjects, proliferated
and secreted IFN-c in response to rMPT83. Furthermore, we have
demonstrated the protective efficacy of both plasmid DNA
expressing MPT83 and rMPT83 protein vaccine in adjuvant
against aerosol infection with M. tuberculosis in mice.
Expression of Rv2873 with an additional N-terminal His-Tag in
the pET19b system yielded a recombinant protein with the
predicted molecular weight of 25.61 kDa, compared to 22.07 kDa
for the amino acid sequence of MPT83. Interestingly, probing
different sub-cellular fractions of M. tuberculosis with mouse anti-
rMPT83 antisera detected a protein band with a relative
molecular mass of 25 kDa. This is consistent with previous reports
that native MPT83 has a Mr of 26 kDa in SDS-PAGE, in part due
Figure 2. Recognition of MPT83 during M. tuberculosis infection in humans. Antigen-specific T cell responses were measured in PBMC from
M. tuberculosis-infected subjects (TB) (n=28) and tuberculin skin test-negative subjects (TST2ve) (n=20). (A) T cell proliferation in response to M.
tuberculosis CFP (circles) or rMPT83 (triangles) protein at 10 mg/ml was measured by the net incorporation of
3H-thymidine; and (B) T cell production
of IFN-c following antigen stimulation was measured by ELISA. Horizontal lines represent the median for each group. The statistical significances were
determined by the Mann-Whitney U-test (****, p#0.0001).
doi:10.1371/journal.pone.0034991.g002
Figure 3. Antigen-specific T cell responses to immunization
with DNA-MPT83. C57BL/6 mice (n=3) were immunized three times
at two-weekly intervals with 100 mg DNA-MPT83 or pcDNA3 control
vector by i.m.i. Four weeks after the final immunization, splenocytes
were harvested and stimulated ex vivo with either rMPT83 (10 mg/ml) or
Con A (3 mg/ml). (A) The numbers of IFN-c-secreting cells/10
6
splenocytes following 16 h of antigen stimulation were enumerated
by ELIspot. (B) The levels of IFN-c released into the supernatants
following 72 h of antigen stimulation were measured by IFN-c ELISA.
Data shown are the means6SEM and the statistical significance was
determined by the Student’s t-test (*, p,0.05; **, p,0.01), and are
representative of three independent experiments.
doi:10.1371/journal.pone.0034991.g003
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whole cell lysate (Fig. 1B, lane 8) and Triton X-114 detergent
soluble fractions of M. tuberculosis, suggesting MPT83 is an integral
membrane protein (Fig. 1B, lane 4). This mirrors studies of
MPB83, which reported its presence in the Triton X-114 soluble
fraction [24]. MPB83 has also been detected on the surface of
M. bovis by flow cytometry using monoclonal antibodies [25].
The M. bovis MPB83 and the closely related protein MPB70 are
major antigens recognised during M. bovis infection of cattle,
acquired by both natural and experimental transmission. Ninety
percent of M. bovis infected cattle develop antibody responses
against MPB83 [26], while 78% of develop delayed-type
hypersensitivity responses to a protein cocktail containing
MPB83 [27]. Furthermore, badgers are a natural reservoir for
M. bovis infection and MPB83 stimulates a strong antibody
response in the majority of infected animals [13,28]. Both MPB83
and MPB70 are abundantly expressed in M. bovis, however
MPB83 is retained in the cell membrane, while MPT70 is secreted
into the culture filtrate [11]. There is variable expression of
MPB83 in different strains of M. bovis BCG, caused by point
mutations in both sigK [18] and Rv0444c [29], encoding the
positive regulator and repressor that control the SigK regulon
containing both mpb83 and mpb70. The wild-type Rv0444c protein
in M. tuberculosis is associated with moderate to low levels of
expression of MPT83 in bacterial cultures [29]. Nevertheless,
MPT83 was readily detected in both the whole cell lysate of
M. tuberculosis H37Rv and the membrane integral proteins
fraction. It is also apparent that the protein is expressed during
infection in vivo, as both TB patients and M. tuberculosis-infected
mice developed strong IFN-c T cell responses against MPT83.
While the current study examined the recognition of MPT83 in
patients with active TB, a recent study of both BCG-vaccinated
and M. tuberculosis-infected healthy subjects in Kuwait reported the
recognition of multiple MPT83-derived peptides by the majority
of subjects, resulting in antigen-induced proliferation and IFN-c
production [30].
Immunization of C57BL/6 mice with MPT83 as either a DNA
or protein vaccine stimulated strong antigen-specific IFN-c
secreting T cell responses. Similar levels of immunogenicity have
been observed in BALB/c mice immunized with RNA encoding
MPT83 [31]. CD4
+ T cells are essential for protective immunity
against M. tuberculosis infection, but they are also critical for the
activation and licensing of CD8
+ T cell responses. M. tuberculosis-
specific CD8
+ T cells contribute to protection, especially during
the chronic phase of experimental infection in mice [32,33].
Overlapping 15mer peptides spanning the MPT83 sequence were
used to locate the dominant H-2
b-restricted CD8
+ T cell epitope
within the peptide MPT83121–135, and the minimal epitope
defined as MPT83127–135, PTNAAFDKL (peptide 13–7). This
peptide had the second highest binding score for nonamers
binding to H-2D
b in both the SYFPEITHI and IEDB epitope
prediction algorithms (Table 1). Immunization with DNA-MPT83
primed for strong CD8
+ T cell responses to the MPT83127–135
peptide following M. tuberculosis challenge (Fig. 8B). Computational
analysis of MPT83 has identified peptides with the potential for
binding to multiple human MHC Class I alleles, suggesting human
CD8
+ T cell epitopes my also exist in the protein [30].
Given that MPT83 was recognized during both human and
murine M. tuberculosis infections, we examined whether the robust
T cell responses induced by MPT83 translated into protection
against M. tuberculosis challenge. Immunization with either
rMPT83 in MPLA/DDA adjuvant emulsion or plasmid encoding
MPT83 significantly reduced both pulmonary and splenic
bacterial loads following M. tuberculosis challenge. This effect is
consistent with the protection against M. tuberculosis infection
induced by an RNA-based vaccine encoding MPT83 in BALB/c
mice [31]. Furthermore, combinations of DNA vaccines, which
included MPT83 as one of several secreted proteins, were also
protective against experimental TB infection [34,35]. DNA
immunization using the M. bovis homolog, MPB83 protected
BALB/c mice against M. bovis challenge as well as stimulating T
cell responses in immunized cattle [15]. When tested in the guinea
pig model of M. bovis infection, plasmid MPB83 significantly
reduced the extent of granulomatous infiltration in the lungs,
although it did not reduce the bacterial load following aerogenic
infection [36]. Early studies with DNA vaccines suggested they
may have limited applicability in humans, but more recent
investigations administrating DNA vaccines into humans using
in vivo electroporation resulted in significantly enhanced DNA
delivery and stimulated robust cellular immune responses,
Figure 4. Identification of H-2
b-restricted T cell peptide epitopes in MPT83. C57BL/6 mice (n=3) were immunized with 100 mg of DNA-
MPT83 or pcDNA3 control vector i.m.i three times at two-weekly intervals. Four weeks post-immunization splenocytes were harvested and stimulated
ex vivo with rMPT83 (10 mg/ml), one of 22 MPT83 15-mer peptides (10 mg/ml) (overlapping by five residues) or Con A (3 mg/ml). (A) The number of
peptide-specific and MPT83-specific IFN-c-secreting T cells were measured by ELIspot after 16 h stimulation; and (B) by ELIspot following depletion of
CD4
+ T cells with the anti-CD4 monoclonal antibody (GK1.5). Data are the means6SEM for replicate samples from the three mice, and are
representative of two independent experiments.
doi:10.1371/journal.pone.0034991.g004
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This study also demonstrated that immunization with rMPT83
protein in MPLA/DDA liposomes was unequivocally protective.
The level of protection was considerable, with approximately one
log10 reduction in bacterial load induced by rMPT83 (Fig. 7),
similar level to the protection afforded by other M. tuberculosis
protein vaccines, which are currently in phase I clinical trials
[21,39,40].
In general, the level of protection stimulated by rMPT83 and
other M. tuberculosis protein vaccines is less than that induced by
BCG, although they have the advantage of increased safety over
BCG in immune-compromised subjects [41]. The potential
application of these subunit vaccines is for boosting the effects
of infant BCG immunization, or, as demonstrated with DNA
encoding Ag85B, for priming prior to BCG to increase the
protection afforded by BCG vaccination [42,43]. The adjuvant
used in the current study, MPLA, is a potent inducer of Th1
responses through the activation of TLR-4 [44]. Interestingly,
rMPT83/MPLA/DDA primed for stronger IFN-c T cell
responses to the whole protein following challenge, while DNA-
MPT83 primed for stronger CD8
+ T cell responses to
MPT83127–135, even though they had similar protective efficacies.
The development of more effective and safe adjuvants for protein
anti-TB vaccines, such as the mycobacterial cell wall component
trehalose-6,6-dimycolate and its synthetic analogue trehalose-6,6-
dibehenate, which induce both Th1 and Th17 responses [45–
47], may further increase the protective efficacy and durability of
these vaccines. MPT83 is an additional protective antigen, which
should be considered for inclusion in future anti-TB vaccines.
Materials and Methods
Ethics Statement
All animal experimental protocols and procedures were
approved by the Animal Ethics Committee of the University of
Sydney with the reference number K75/5-2008/3/4849. The
blood samples were collected with informed written consent from
patients and ethical approval for the clinical investigations was
obtained from the Sydney South West Area Health Service
Human Ethics Committee.
Mice
Six to eight weeks old female C57BL/6 mice were obtained
from the Animal Resource Centre (Perth, Australia) and
maintained under specific pathogen-free conditions at the animal
facility at the Centenary Institute. All mice were housed in
temperature-controlled rooms with unrestricted access to food and
water.
Bacterial Strains and Experimental Infection
M. tuberculosis H37Rv (ATCC 27294) and M. bovis BCG Pasteur
were grown in Middlebrook 7H9 broth media supplemented with
10% Middlebrook ADC enrichment (Difco, Detroit, MI) and
0.05% polysorbate 80 (Sigma, St Louis, MO). Cultures were
grown to mid-log phase then stored at 280uC. Frozen aliquots of
M. tuberculosis were resuspended in distilled water for aerosol
infection. Mice were infected with approximately 100 CFU of
Figure 5. Confirmation of H-2
b-restricted T cell epitopes in
MPT83. C57BL/6 mice (n=3) were immunized with 100 mg of DNA-
MPT83 or pcDNA3 control vector by i.m.i three times at two-weekly
intervals. Four weeks post-immunization, mice were harvested, and the
pooled splenocytes were labelled with anti-CD3-PerCP, anti-CD4-
Alexaflour 700 and anti-CD8-APC-Cy7 mAbs and the CD4
+ and CD8
+
T cells were separated by flow cytometry. The CD4
+ (A) and CD8
+ (B) T
cells were stimulated with irradiated splenocytes and the peptides 1, 5,
9, 13 and 14 (10 mg/ml), MPT83 (10 mg/ml) or ConA (3 mg/ml), and the
antigen-specific IFN-c responses were measured by ELIspot after 16 h.
Data represent the means of replicates for each treatment, and are
representative of two independent experiments.
doi:10.1371/journal.pone.0034991.g005
Table 1. Sequence of overlapping peptides spanning peptide
13(121–135) of MPT83 and the predicted scores* for binding of
the peptides to H-2K
b and H-2D
b.
Peptide
name Sequence SYFPEITHI scores*
H-2K
b H-2D
b
13 EYTVFAPTNAAFDKL - -
13-1 EYTVFAPTN 0 3
13-2 YTVFAPTNA 0 4
13-3 TVFAPTNAA 0 0
13-4 VFAPTNAAF 0 8
13-5 FAPTNAAFD 0 21
13-6 APTNAAFDK 0 2
13-7 PTNAAFDKL 0 12
13-8 TNAAFDKLA 0 2
13-8.2 TNAAFDKL - 22
*Predicted binding scores from the website: http://www.syfpeithi.de/Scripts/
MHCServer.dll/EpitopePrediction.htm.
doi:10.1371/journal.pone.0034991.t001
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e34991Figure 6. Minimal CD8
+ T cell epitope within peptide 13 of MPT83. C57BL/6 mice (n=3) were immunized with 100 mg DNA-MPT83 (&)o r
pcDNA3 (%) control vector by i.m.i three times at two-weekly intervals. Four weeks post-immunization, the mice were harvested and the splenocytes
were stimulated with nonameric peptides spanning the sequence of peptide 13 and overlapping by one residue (Table 1) at 10 mg/ml, MPT83 (10 mg/
ml) and ConA (3 mg/ml) and number of peptide-specific IFN-c secreting T cells were measured by ELIspot after 16 h. Data shown are the means6SEM
for triplicate samples from three mice and representative of two independent experiments. The statistical significance of differences was determined
by the Student’s t-test (*, p,0.05; ***, p,0.001, ****, p,0.0001).
doi:10.1371/journal.pone.0034991.g006
Figure 7. Protective efficacy induced by DNA-MPT83 and rMPT83 immunization. C57BL/6 mice (n=5) were immunized with 100 mgo f
DNA-MPT83 and control vector pcDNA3 by i.m.i. (Panels A and B) or 10 mg of rMPT83 in MPLA/DDA by s.c.i. (Panels C and D) three times at two-
weekly intervals. Six weeks following the final immunization, mice were infected by aerosol with M. tuberculosis H37Rv. Additional mice were
immunized with 5610
5 CFU of BCG once by s.c.i. 12 weeks before challenge with M. tuberculosis H37Rv. After 28 days, mice were sacrificed, and the
bacterial loads in the lung and the spleen were determined by CFU enumeration following culture on Middlebrook 7H11 media. The data are the
means 6 SEM and are representative of three independent experiments for DNA-MPT83 and two experiments for rMPT83. The statistical significance
between groups was determined by analysis of variance (*, p,0.05, **, p,0.01, ***, p,0.001).
doi:10.1371/journal.pone.0034991.g007
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(Glas-Col, Terre Haute, IN), and the infectious dose was
confirmed by plating serial dilutions of the lung homogenates
harvested 24 h after infection. Mice were immunized with
5610
5 CFU of M. bovis BCG in sterile PBS by subcutaneous
injection (s.c.i.) at the base of the tail. The bacterial loads in the
lung and spleen of all infected mice were determined by plating
serial dilutions of the tissue homogenate onto Middlebrook 7H11
Bacto agar, supplemented with 10% OADC (Difco), and
incubated at 37uC in a humidified incubator for 21 days.
Construction of Plasmid Vectors
The MPT83 expression vector was constructed with the
complete coding sequence of MPT83 (Rv2873). The full-length
open reading frame was amplified from H37Rv genomic DNA
using the forward primer 59-GAATTCATGATCAACGTT-
CAGGCC-39 and the reverse primer 59-GATATCTATCACGT-
GATCTATCGGC-39. The amplicon was cloned into an inter-
mediate vector (pCR2.1, Invitrogen). The complete MPT83 gene
was excised using EcoRI and EcoRV and blunt ligated into a BamHI
digested expression vector, pET19b (Novagen, Madison, WI)
carrying an N-terminal histidine tag, to form pSM2. The MPT83
DNA vaccine was constructed by inserting the whole MPT83 gene
into the eukaryotic expression vector pcDNA3 (Invitrogen,
Carlsbad, CA) under the control of the CMV IE promoter to
yield DNA-MPT83. The pcDNA3 vector served as control
vaccine.
Recombinant Protein Expression and Purification
Recombinant MPT83 expression from pSM2 was driven by the
T7 in E. coli BL21 (DE3). For large-scale production of
recombinant protein, an overnight starter culture was used to
seed Luria Bertani (LB) broth (Difco) supplemented with
ampicillin (100 mg/ml) and incubated at 37uC for 16 h with
agitation. This resulted in the over-expression of cytoplasmic
MPT83 protein with an N-terminal His-tag that aggregated as
insoluble inclusion bodies. The recombinant protein was purified
by solubilizing the inclusion bodies in 100 ml of 8 M urea buffer
(8 M urea, 0.3 M NaCl, Sodium Phosphate buffer pH 7.6) per
litre of culture and slowly agitating at 4uC. The solubilized protein
was purified by a Talon Co
2+ charged immobilized metal affinity
chromatography (IMAC) system (Clontech, Mountain View, CA),
according to the manufacturer’s instructions, and dialysed against
Tris buffer (50 mM, pH 7.5).
SDS-PAGE and Immunoblotting
Denatured samples were separated on a 12% polyacrylamide
gel and proteins were visualised by Coomassie blue (Sigma)
staining. For protein immunoblotting, following electrophoresis,
proteins were transferred to a BioTrace PVDF 0.45 mm pore sized
membrane (Pall, Pensacola, FL) with a Trans Blot Cell (Biorad).
The resulting membrane was blocked with 5% skim milk in PBS
with 0.05% polysorbate 20 (PBST) (Sigma) for 1 h at room
temperature and then incubated with mouse anti-rMPT83 serum
for 2 h at room temperature (1:500 dilution in PBST). The blots
were then washed and incubated with horseradish peroxidase
(HRP) conjugated sheep anti-mouse IgG monoclonal antibody for
2 h at room temperature (GE Heathcare, Buckinghamshire, UK).
The bands were detected using SuperSignal West Pico Chemilu-
minescent substrate (Thermo, Waltham, MA) according to the
manufacturer’s instructions and the images captured using the
Image Station 4000MM imager (Kodak, Rochester, NY) and
analysed using the Kodak IM software (Kodak).
Peptide Preparation
A set of 22 15-mer peptides overlapping by five amino acids
spanning the MPT83 protein and the nine peptides for fine
mapping (Table 1) were synthesized by Genscript (Piscataway, NJ).
Figure 8. T cell responses following immunization with DNA-
MPT83 and rMPT83, and M. tuberculosis challenge. C57BL/6 mice
(n=5) were immunized with 100 mg of DNA-MPT83 and control vector
pcDNA3 by i.m.i. or 10 mg of rMPT83 in MPLA/DDA by s.c.i. three times
at two-weekly intervals. Six weeks following the final immunization,
mice were infected by aerosol with M. tuberculosis H37Rv. Additional
mice were immunized with 5610
5 CFU of BCG once by s.c.i. 12 weeks
before challenge with M. tuberculosis H37Rv. After 28 days, mice were
sacrificed, and the MLN was harvested and stimulated ex vivo with CFP
at 3 mg/ml (A), Peptide 13 at 10 mg/ml (B), and MPT83 at 10 mg/ml (C).
T h ed a t aa r et h em e a n 6SEM and are representative of two
experiments. The statistical significance between groups was deter-
mined by analysis of variance (***, p,0.001).
doi:10.1371/journal.pone.0034991.g008
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PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e34991The lyophilized peptides were resolubilized according to the
supplier’s instructions at 10 mg/ml and stored at 230uC until use.
Immunization of Animals
Mice were immunized with 100 mg of plasmid DNA resus-
pended in 100 ml PBS. Fifty microliters were administered by
intramuscular injection (i.m.i) into each quadriceps of an
anaesthetized mice using an 1 ml insulin syringe with a 27 G
needle (Terumo, Somerset, NJ) [48]. The rMPT83 protein was
mixed with an adjuvant formulation of dimethyl-dioctadecyl
ammonium bromide (DDA) and monophosphoryl lipid A (MPLA)
(Sigma) to deliver 10 mg MPT83, 500 mg DDA and 25 mg MPLA
in 200 ml and injected subcutaneously into an anaesthetized mice
at the base of the tail, twice, two weeks apart with an 1 ml insulin
syringe harbouring a 27 G needle [49]. Mice were tested for
immune responses four weeks after the final immunization or
challenged with M. tuberculosis to assess protective efficacy six weeks
after the final immunization to minimize any non-specific effects of
the DNA plasmid or adjuvant.
Polyclonal Anti-serum to rMPT83
For the preparation of mouse anti-sera, three mice were
immunized with 10 mg of rMPT83 in DDA/MPLA as described
above. The mice were bled two weeks after the final immuniza-
tion, and the specificity of the binding of the sera was assessed by
protein immunoblotting.
Murine T Lymphocyte Responses
Single-cell suspensions were prepared from the spleens of
immunized animals and the production of IFN-c following in vitro
stimulation was measured. Splenocytes were plated at a density
2610
5 cells per well in a 96-well U-bottom tissue culture plate
(BD, Franklin Lake, NJ) and incubated in RPMI media (Gibco,
Carlsbad, CA) supplemented with 50 mM 2-mercaptoethanol (2-
ME) and 10% foetal bovine serum (FBS). The cells were
stimulated with rMPT83 protein (10 mg/ml), the overlapping
peptides (10 mg/ml), and the controls Concanavalin A (Con A,
3 mg/ml) or media alone. Following incubation at 37uCi n5 %
CO2 for 72 h, the supernatants were collected for analysis.
The IFN-c sandwich ELISA was performed by coating 96-well
ELISA plates (Corning, Lowell, MA) with rat anti-IFN-c
monoclonal antibodies AN18 (1.5 mg/ml, Endogen, Woburn,
MA) followed by blocking with 3% BSA. The culture supernatants
and the serial dilutions of the IFN-c standards (Genzyme,
Cambridge, MA) ranging from 5000 pg/ml to 39 pg/ml were
added to the ELISA plate for 2 h incubation at room temperature.
Following washing, the plates were incubated with the secondary
antibody XMG1.2-bio (2 mg/ml, Endogen) followed by strepavi-
din-HRP. The IFN-c levels were detected by the addition of 2,29-
azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS) substrate
solution (Sigma) and the absorbance was read at 405 nm and
492 nm with the Multiskan EX plate reader (Thermo) and
background absorbance from the unstimulated samples were
subtracted from all test samples before analysis.
The numbers of antigen-specific IFN-c secreting cells were
determined by ELIspot. 96-well Immobilon-P plates (Millipore,
Bedford, MA) were coated with AN18, 15 mg/ml (Endogen).
Single-cell suspensions of splenocytes were plated at a density of
2610
5 cells per well and incubated in RPMI media (Gibco)
supplemented with 50 mM 2-ME and 10% FBS. The cells were
stimulated with rMPT83 protein (10 mg/ml), the overlapping
peptides (10 mg/ml), and the controls Con A (3 mg/ml) or media
alone. Following 20 h incubation at 37uCi n5 %C O 2, the plates
were washed with PBS-Tween20 (0.05% v/v) and incubated for
1 h with XMG1.2-bio (5 mg/ml, Endogen) followed by Avidin-
Alkaline Phosphatase (Sigma) conjugate. Spots were visualised by
incubation with AP substrate (Biorad). The numbers of spot-
forming cells (SPC) were enumerated with an automated ELIspot
reader system (AID, Strasburg, Germany). The numbers of SPC
from the unstimulated wells were subtracted from all samples
before statistical analysis.
Cell Sorting
Single-cell suspensions were prepared from three spleens per
group, pooled and the non-T lymphocytes were depleted by
incubation with rat anti-CD19, anti-B220, anti-CD11b and TER-
119 monoclonal antibodies and separated using anti-rat IgG
microbeads and LS columns by MACS (Miltenyi biotec, Bergisch
Gladbach, Germany). The enriched T cells lymphocytes were
stained with anti-CD3 PerCP, anti-CD4 Alexafluor 700 and anti-
CD8 APC-Cy7 and sorted with FACSaria II (BD). The purities of
the sorted CD4
+ and CD8
+ T cells was determined by flow
cytometry and were 97% and 91%, respectively. In IFN-c ELIspot
assays where purified CD4
+ or CD8
+ T cells were used,
splenocytes irradiated with 2000 rads of c radiation were used as
syngenic antigen presenting cells at a ratio of 1:1.
Human T Lymphocyte Responses
Venous blood was collected with informed consent from
patients with active tuberculosis (n=28) and tuberculin skin test
(TST) negative subjects (n=20) from the Chest Clinic at Royal
Prince Alfred Hospital, Sydney. Human peripheral blood
mononuclear cells (PBMCs) were purified by Ficoll-Paque
gradient centrifugation using Histopaque-1077 (Sigma). The
purified PBMCs were cultured at a density of 2.5610
5 cells in
AIM-V serum free medium (Gibco) supplemented with l-
glutamine, gentamicin (10 mg/ml) and streptomycin (50 mg/ml).
Cells were stimulated with 10 mg/ml of rMPT83 or M. tuberculosis
culture filtrate protein (CFP) (provided by NIH contract at
Colorado State University, USA), or media alone. After five days
incubation at 37uCi n5 %C O 2, the supernatant was collected
and the levels of IFN-c secreted into the supernatant was
measured using the OptEIA
TM Human IFN-c ELISA set (BD) in
accordance to the manufacturer’s instructions. The cells were
then pulsed with 1 mCi of
3H-thymidine (MP Biomedicals, Solon,
OH) per well for 16 h. The level of incorporated
3H-thymidine
was determined by liquid scintillation spectroscopy with the
Microbeta Luminescence Counter (Perkin-Elmer, Waltham,
MA). Specific lymphocyte proliferation was expressed as a delta
counts per minute (DCPM), calculated as the mean CPM for
antigen-stimulated culture wells subtracted by the mean CPM for
unstimulated culture wells.
Statistical Analysis
The significance of the differences in human T cell proliferation
and IFN-c responses were analysed by the Mann-Whitney U-test.
The differences in murine T cell responses between immunized
and non-immunized mice were analysed using an unpaired
Student’s t-test. The differences in bacterial load were assessed
using one-way analysis of variance (ANOVA). Statistical analysis
was performed using the GraphPad Prism 5 software (GraphPad
Software, La Jolla, CA). The differences were considered
significant when the P values were #0.05.
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